Skip to content

Mold Allergy in Austria: Clinical Relevance of Alternaria Alternata and Related Species

Pilot Study Regarding Mold Allergy in Austria: Clinical Relevance of Alternaria Alternata and Related Species

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05101733
Enrollment
70
Registered
2021-11-01
Start date
2021-10-14
Completion date
2023-07-31
Last updated
2022-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy, Fungal Allergy

Keywords

Allergy, Fungal allergy, Alternaria alternata

Brief summary

Mold allergies are becoming increasingly important among the population. Increasing amounts of fungal spores are analyzed in air-samples because of urbanization, industrialization of food products and climate change. Mold also grows indoor and hence lead to additional health complaints. Alternaria alternata, and its only major allergen Alt a 1, is the most important fungus for allergy sufferers. Alternaria alternata can not only cause allergic symptoms but can also cause intensified asthmatic symptoms. Besides Alternaria alternata, there are over 700 other species of the genus Alternaria. The influence of these other species on allergic symptoms is poorly understood. Furthermore, prevalence and incidence of an allergy to Alternaria alternata among the Austrian population is not known. Estimates range between 1-5% among the Austrian population. This study aims to further investigate the incidence and characteristics of an allergy to Alternaria in Austria. This will be investigated with the help of participants (50 Alternaria allergy sufferers and 20 non allergic participants), spore counts in Austria and crowd-sourced symptom data.

Interventions

DIAGNOSTIC_TESTNasal provocation

Nasal provocation with Alternaria alternata extract. Changes in nasal mucosa are measured with a rhinomanometry device

DIAGNOSTIC_TESTSkin-Prick Test

Skin-Prick-Test is administered to determine an allergy against Alternaria

DIAGNOSTIC_TESTBlood draw

For further analysis

Allergy sufferers: After nasal provocation Non-allergics: After administration of isotonic nasal spray

Sponsors

Medical University of Vienna
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Participants will be healthy people over 18 years of age. Allergic participants should have an allergic reaction against Alternaria, visible in the Skin-Prick-Test. Furthermore symptom data in the pollen diary of the Austrian Pollen Information Service should be existing

Exclusion criteria

* Subjects participating in a pharmacological study, pregnant subjects and subjects with an existing infectious- and/or autoimmune disease

Design outcomes

Primary

MeasureTime frameDescription
Prevalence, Immunoglobulin-E (IgE)-antibodies to selected Alternaria species12 monthsDetermine the prevalence of sensitization to multiple Alternaria species in the Austrian population

Secondary

MeasureTime frameDescription
Cytokine-profile (e.g. Interleukin-13, Interleukin-5, Interleukin-10, TNFalpha, IFNgamma) upon Alt a 1 incubation12 monthsChanges in the immun response when ligand-binding mononuclear cells from the blood to Alt a 1, characterized by the cytokine profile (Th1/Th2/regulatory) and the cell population (B- and T-cells, macrophages/monocytes)

Countries

Austria

Contacts

Primary ContactMarkus Berger, Dr.
markus.berger@meduniwien.ac.at+4369918939871

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026